Cite
Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience.
MLA
Beyar-Katz, Ofrat, et al. “Thrombopoietin Receptor Agonist for Treating Bone Marrow Aplasia Following Anti-CD19 CAR-T Cells—single-Center Experience.” Annals of Hematology, vol. 101, no. 8, Aug. 2022, pp. 1769–76. EBSCOhost, https://doi.org/10.1007/s00277-022-04889-6.
APA
Beyar-Katz, O., Perry, C., On, Y. B., Amit, O., Gutwein, O., Wolach, O., Kedar, R., Pikovsky, O., Avivi, I., Gold, R., Ben-Ezra, J., Shasha, D., Ami, R. B., & Ram, R. (2022). Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experience. Annals of Hematology, 101(8), 1769–1776. https://doi.org/10.1007/s00277-022-04889-6
Chicago
Beyar-Katz, Ofrat, Chava Perry, Yael Bar On, Odelia Amit, Odit Gutwein, Ofir Wolach, Rotem Kedar, et al. 2022. “Thrombopoietin Receptor Agonist for Treating Bone Marrow Aplasia Following Anti-CD19 CAR-T Cells—single-Center Experience.” Annals of Hematology 101 (8): 1769–76. doi:10.1007/s00277-022-04889-6.